Pharma-Investor's Perspective on Gene Therapy

The Future of Cell and Gene Therapy

“Each passing year, the success of cell and gene therapy (CGT) becomes clearer, more widely covered in the media, and is increasingly the focus of a rapidly growing society of researchers. Making sense of this extensive ecosystem is no small feat, but by using a data-driven approach, we can get closer to determining what the future holds for CGT.

Pharma-Investor's Perspective on Gene Therapy

CGT has emerged as one of the most exciting areas of biotechnology. Its buzz can be attributed to the hope these therapies hold for patients with rare and often deadly inherited diseases; the scientific promise and intrigue of gene editing; and the business opportunity that these revolutionary therapies with lucrative price tags hold.

But what do we really know about cell and gene therapy? What proverbial gold will be found at the end of this rainbow?“


READ MORE …

Motley-Fool's monthly speculation on cancer treatment stocks

3 Cancer Treatment Stocks to Buy in March

Motley-Fool's monthly speculation on cancer stocks

There has been tremendous progress in the battle against cancer, but it remains the second leading cause of death in the U.S., behind heart disease. That means there is plenty of work left to be done.

So which cancer-focused companies are worth watching? We asked three Motley Fool healthcare contributors to weigh in, and they called out Blueprint Medicines(NASDAQ:BPMC), Halozyme Therapeutics (NASDAQ:HALO), and Merck (NYSE:MRK). 


READ MORE …